 Cyclin-Dependent Kinase Inhibitor p16
"Cyclin-Dependent Kinase Inhibitor p16" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A product of the p16 tumor suppressor gene (GENES, P16). It is also called INK4 or INK4A because it is the prototype member of the INK4 CYCLIN-DEPENDENT KINASE INHIBITORS. This protein is produced from the alpha mRNA transcript of the p16 gene. The other gene product, produced from the alternatively spliced beta transcript, is TUMOR SUPPRESSOR PROTEIN P14ARF. Both p16 gene products have tumor suppressor functions.
| Descriptor ID |
D019941
|
| MeSH Number(s) |
D12.644.360.225.200 D12.776.167.187.200 D12.776.476.225.200 D12.776.624.776.355.200
|
| Concept/Terms |
Cyclin-Dependent Kinase Inhibitor p16- Cyclin-Dependent Kinase Inhibitor p16
- Cyclin Dependent Kinase Inhibitor p16
- CDKN2 Protein
- CDKN2A Protein
- MTS1 Protein
- p16INK4 Protein
- p16(INK4A)
- INK4A Protein
- Protein, INK4A
- Cyclin-Dependent Kinase Inhibitor-2A
- Cyclin Dependent Kinase Inhibitor 2A
- Multiple Tumor Suppressor-1
- Multiple Tumor Suppressor 1
- Cdk4-Associated Protein p16
- Cdk4 Associated Protein p16
- p16INK4A Protein
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase Inhibitor p16".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase Inhibitor p16".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase Inhibitor p16" by people in this website by year, and whether "Cyclin-Dependent Kinase Inhibitor p16" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 5 | 5 | | 1997 | 1 | 3 | 4 | | 1998 | 1 | 0 | 1 | | 1999 | 0 | 3 | 3 | | 2000 | 0 | 1 | 1 | | 2002 | 1 | 1 | 2 | | 2003 | 1 | 1 | 2 | | 2004 | 2 | 1 | 3 | | 2005 | 0 | 2 | 2 | | 2006 | 1 | 1 | 2 | | 2007 | 1 | 1 | 2 | | 2008 | 3 | 0 | 3 | | 2009 | 1 | 2 | 3 | | 2010 | 2 | 5 | 7 | | 2011 | 1 | 2 | 3 | | 2012 | 1 | 3 | 4 | | 2013 | 1 | 2 | 3 | | 2014 | 0 | 2 | 2 | | 2015 | 1 | 1 | 2 | | 2016 | 1 | 5 | 6 | | 2017 | 0 | 1 | 1 | | 2018 | 1 | 1 | 2 | | 2019 | 0 | 1 | 1 | | 2021 | 2 | 0 | 2 | | 2022 | 0 | 2 | 2 | | 2023 | 0 | 1 | 1 | | 2025 | 1 | 4 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase Inhibitor p16" by people in Profiles.
-
Walrath TM, Evans MR, Meza Monge K, Najarro KM, Orlicky DJ, Idrovo JP, McMahan RH, Kovacs EJ. Impaired intestinal cell proliferation parallels increased senescence after burn injury in aged mice. Am J Physiol Gastrointest Liver Physiol. 2026 01 01; 330(1):G1-G9.
-
Sine CC, Watts LP, Fernandez B, Marikar N, Wang J, Knudsen ES, Witkiewicz AK, Spencer SL. p16 expression confers sensitivity to CDK2 inhibitors in cyclin E1-driven ovarian cancers. Sci Signal. 2025 Nov 25; 18(914):eadv0415.
-
McGivney GR, Brockman QR, Borcherding N, Scherer A, Rauckhorst AJ, Gutierrez WR, Solst SR, Heer CD, Warrier A, Floyd W, Kirsch DG, Knepper-Adrian VL, Laverty EA, Roughton GA, Spitz DR, Taylor EB, Dodd RD. Somatic CRISPR tumorigenesis and multiomic analysis reveal a pentose phosphate pathway disruption vulnerability in MPNSTs. Sci Adv. 2025 Aug 15; 11(33):eadu2906.
-
Patel R, Fountzilas C, Horowitz M, Schultz E, Clayback KM, Knudsen ES, Witkiewicz AK, Onel K. Pancreatic adenocarcinoma in a patient with a germline RB1 pathogenic variant. Fam Cancer. 2025 05 26; 24(2):46.
-
Kumarasamy V, Wang J, Roti M, Wan Y, Dommer AP, Rosenheck H, Putta S, Trub A, Bisi J, Strum J, Roberts P, Rubin SM, Frangou C, McLean K, Witkiewicz AK, Knudsen ES. Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle. Nat Commun. 2025 Feb 09; 16(1):1476.
-
Masugi Y, Takamatsu M, Tanaka M, Hara K, Inoue Y, Hamada T, Suzuki T, Arita J, Hirose Y, Kawaguchi Y, Nakai Y, Oba A, Sasahira N, Shimane G, Takeda T, Tateishi K, Uemura S, Fujishiro M, Hasegawa K, Kitago M, Takahashi Y, Ushiku T, Takeuchi K, Sakamoto M. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression. J Pathol Clin Res. 2023 09; 9(5):339-353.
-
Li Z, Liu P, Wang Z, Zhang Z, Chen Z, Chu R, Li G, Han Q, Zhao Y, Li L, Miao J, Kong B, Song K. Prevalence of human papillomavirus DNA and p16INK4a positivity in vulvar cancer and vulvar intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol. 2023 04; 24(4):403-414.
-
Hamad SH, Montgomery SA, Simon JM, Bowman BM, Spainhower KB, Murphy RM, Knudsen ES, Fenton SE, Randell SH, Holt JR, Hayes DN, Witkiewicz AK, Oliver TG, Major MB, Weissman BE. TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. Oncogene. 2022 06; 41(25):3423-3432.
-
Wilde DC, Castro PD, Bera K, Lai S, Madabhushi A, Corredor G, Koyuncu C, Lewis JS, Lu C, Frederick MJ, Frederick AM, Haugen AE, Zevallos JP, Sturgis EM, Shi J, Huang AT, Hernandez DJ, Skinner HD, Kemnade JO, Yu W, Sikora AG, Sandulache VC. Oropharyngeal cancer outcomes correlate with p16 status, multinucleation and immune infiltration. Mod Pathol. 2022 08; 35(8):1045-1054.
-
Sturmlechner I, Zhang C, Sine CC, van Deursen EJ, Jeganathan KB, Hamada N, Grasic J, Friedman D, Stutchman JT, Can I, Hamada M, Lim DY, Lee JH, Ordog T, Laberge RM, Shapiro V, Baker DJ, Li H, van Deursen JM. p21 produces a bioactive secretome that places stressed cells under immunosurveillance. Science. 2021 Oct 29; 374(6567):eabb3420.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|